Shah Metacorp Limited has informed the Exchange regarding Outcome of Committee Meeting held on July 05, 2025.
SHAH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shah Metacorp Limited's Committee of Directors met on July 5, 2025, and approved the allotment of 63,00,000 equity shares (out of a total 6,65,00,000 approved shares) on a preferential basis to non-promoter allottees. The shares were issued at a price of ₹4.71 each, raising approximately ₹2.97 crore in total. The allottees are Hemlataben Patel (50,00,000 shares for ₹2.36 crore) and Jayani Healthcare (13,00,000 shares for ₹61.23 lakh). This follows an EGM approval on March 5, 2025, and in-principle approvals from BSE (June 24) and NSE (June 23). After the allotment, Hemlataben Patel will hold 0.56% and Jayani Healthcare's stake will rise from 0.42% to 0.56% of the company.
This is a small tranche (₹2.97 crore) of a larger ₹31.3 crore planned preferential issue, resulting in minor equity dilution for existing shareholders. The non-promoter nature of the allottees and the low issue price (relative to typical preferential pricing) suggest capital raising, but the dilution impact is modest at this stage.